PT-141 (Bremelanotide) is the first of a new class of drugs called
melanocortin agonists being developed to treat sexual dysfunction.
The mechanism of action of PT-141
(Bremelanotide) may offer significant safety and efficacy
benefits over currently available products because it acts on
the pathway that controls sexual function without acting directly
on the vascular system. Clinical data indicates that PT-141 (Bremelanotide)
may be effective in treating a broad range of patients suffering
from ED. The nasal formulation of PT-141 (Bremelanotide) being
developed is as convenient as oral treatments, is more patient-friendly
than invasive treatments for ED, such as injections and trans-urethral
pellets, and appears to result in a rapid onset of action.
About Erectile Dysfunction (ED)
ED is defined as the consistent inability to attain and maintain
an erection sufficient for sexual intercourse. The condition is
correlated with increasing age, cardiovascular disease, hypertension,
diabetes, hyperlipidemia and smoking. In addition, certain prescription
drugs and psychogenic issues may contribute to ED. It is estimated
that some degree of ED affects one half of all men over the age
of 40 and that 150 million men worldwide suffer from ED.
